Please login to the form below

Not currently logged in
Email:
Password:

paliperidone palmitate

This page shows the latest paliperidone palmitate news and features for those working in and with pharma, biotech and healthcare.

Allergan and Gedeon finally get antipsychotic green light

Allergan and Gedeon finally get antipsychotic green light

Once-monthly examples include Otsuka/Lundbeck's Abilify Maintena (aripiprazole) and Johnson and Johnson's Invega Sustenna (paliperidone palmitate), while J&J is also developing a three-monthly paliperidone depot that

Latest news

  • More waiting for Allergan and Gedeon Richter's antipsychotic More waiting for Allergan and Gedeon Richter's antipsychotic

    The drug is one of several new antipsychotic agents expected to drive growth in the schizophrenia market in the coming years, along with Johnson &Johnson's three-monthly paliperidone palmitate depot,

  • FDA approves J&J’s schizophrenia drug Invega Trinza FDA approves J&J’s schizophrenia drug Invega Trinza

    The FDA has approved Johnson &Johnson's Invega Trinza (three-month paliperidone palmitate) for schizophrenia. ... Before patients can be started on the drug they must first be taking Janssen's Invega Sustenna, a one-month form of paliperidone palmitate,

  • J&J gets quicker review for schizophrenia depot in US J&J gets quicker review for schizophrenia depot in US

    The US FDA has granted priority review status to Johnson &Johnson's paliperidone palmitate depot, which if approved will become the first schizophrenia drug that can be administered just four times ... The current formulation of paliperidone - sold as

  • Double win for J&J's schizophrenia franchise Double win for J&J's schizophrenia franchise

    Added to that, the pharma company has just stopped a trial of its three-monthly formulation of Risperdal (risperidone) follow-up paliperidone palmitate on positive results, setting up a filing later ... Three-monthly paliperidone. Meanwhile, J&J could

  • OTC recovery helps J&J in first-quarter OTC recovery helps J&J in first-quarter

    The company said the sales increase was also helped by new pharmaceutical product introductions, including its depot antipsychotic Invega Sustenna/Xeplion (paliperidone palmitate), which grew 76 per cent to $284m in

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...

Infographics